We got a number of important drugs from the Celgene acquisition, says Bristol Myers Squibb CEO

Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk recent acquisitions made by the company, whats ahead for BMY and much more.

[@Alduinsshadow148]

With nearly 100 Billion in assets to acquire new drugs and raise prices by 10% each year BMY is one of the cheapest companies in the sp500 to buy as a dividend grower long term also with the aging boomer population healthcare will revert back to the mean.

[@zeshanfarooqui1]

It will continue to drop. Their main revenues are concentrated on drugs going off patent (eliquis and nivolumab) and Revlimid is off patent. Their acquisitions are weak. Did you see they bought Mirati for its G12C inhibitor, adagrasib. This drug is weak versus what is coming from Lilly and Merck.

[@jeffreymancini409]

@@zeshanfarooqui1 Dude you know zero about mental health treatment and the impact of how the Karuna acquisition will fundamentally change the treatment of schizophrenia. That drug is set for September 2024 FDA approval.

[@zeshanfarooqui1]

@@technoidX681 that’s typical for Pharma. Internal development is rare. Right now with a tight financial markets biotechs are looking for lifelines of getting cash for their assets. This how many Pharma add to their pipeline

[@jeffreymancini409]

@@technoidX681 Does it matter?

[@DorothyTaylor-c4j]

Cathryn Ford

[@RoxieRingelspaugh-n6r]

Reinhold Mews

[@VoncileKandarian-v4w]

Ernser View